Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one.
Delays in Diagnosis
It has been a wonderful year for autoinflammatory diseases at the ACR Annual Meeting.
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.
Highlights from Tuesday and Wednesday day 3 and 4 of the ACR Annual meeting in Chicago, included:
Rheumatology Roundup - Drs. Artie Kavanaugh and Jack Cush
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies (ICI) showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.
Pedro Castillo @_Castillo_Pedro ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
TheDaoIndex @KDAO2011 ( View Tweet )
Chris Wincup @chriswincup ( View Tweet )
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
